Advancing Care in Unresectable Hepatocellular Carcinoma

To participate in this activity, please:

Hepatocellular carcinoma (HCC) prevalence is currently increasing and is a major source of morbidity and mortality in the US and around the world. Management of HCC requires multidisciplinary collaboration across several specialties, with hepatologists and oncologists fulfilling key roles within the care team. Dr. Amit Singal provides learners with a comprehensive review of HCC, beginning with the epidemiology and burden of disease and taking learners through optimal systemic management. Dr. Singal will provide practical guidance related to the use of tyrosine kinase inhibitors, VEGF inhibitors, and immunotherapy in patients with HCC, including guideline recommendations, adverse event management, and the role of combination therapy.

Course Credit:

1.25 AMA PRA Category 1 CreditsTM


Opens: 2021-03-18
Closes: 2022-03-18

Target Audience:

This activity was developed for national audience of heptalogists, as well as medical and radiation oncologists, interventional radiologists, and hepatic surgeons.

This educational activity is supported by medical education grants from Bayer HealthCare Pharmaceuticals; Exelixis, Inc.; and Novocure Inc.

    Presenting Faculty

  • Amit G. Singal, MD, MS

    Chief of Hepatology
    Medical Director, Liver Tumor Program
    Professor, Department of Internal Medicine
    UT Southwestern Medical Center
    Dallas, Texas

Learning Objectives

  • Discuss the potential clinical impact of ongoing clinical trials evaluating novel therapies for patients with advanced hepatocellular carcinoma (HCC)
  • Assess the current and emerging first- and second-line systemic therapy for patients with advanced HCC
  • Create personalized treatment plans that take into account HCC and underlying liver disease pathogenesis and incorporate screening and multidisciplinary care
  • Develop individualized treatment strategies for patients with advanced HCC, including optimal management of adverse events/immune-related adverse events on the background of underlying liver disease

Faculty Disclosures

Amit G. Singal, MD, MS

Consultant: Bayer HealthCare Pharmaceuticals; Bristol Myers Squibb; Eisai Inc.; Exact Sciences Corp.; Exelixis, Inc.; Genentech, Inc.; GRAIL, Inc.; Glycotest, Inc.; Wako Diagnostics

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Jessica Martin, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.